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When cells die – a comprehensive evaluation
of apoptosis and programmed cell death
Edited by Richard A Lockshin, Zahra Zakeri and
Jonathan L Tilly: Publication details, pp. 504, £65,
ISBN 0–471–16569–7. Wiley-Liss: New York, 1998
￿When cells die￿￿ is a collection of reviews written by several
different international researchers, from disciplines including cell
and developmental biology, neuroscience, immunology, cancer
research and virology. It groups these varied views on cell death
into five sections: the phenomenon of cell death, themes and
approaches to cell death, cell death when mitosis is high and
evanescence is desirable, cell death in long-lived cells and the clin-
ical relevance of apoptosis. The total of seventeen chapters cover a
range of topics including the evolutionary origin of programmed
cell death, caspases, cell death in plants, apoptotic signalling in
lymphocytes, and importance in cancer therapy.
A substantial book with high aspirations, it aims to inspire those
not yet captive of the field to evaluate the meaning and impact of
cell death in their own particular discipline. It targets both the
mature student and scientist, and addresses a great diversity of
themes which unfortunately lack a unifying thread. The reader is
presented with a host of different definitions of terms related to
cell death, referring to very similar morphological concepts. This,
perhaps, would deter a novice. It is also clear from the sometimes
contradictory accounts by various authors that there are consider-
able and fundamental difficulties related to studying dying cells.
There is no mention of the newer experimental candidates such as
Annexin V and clusterin, but this is probably just a reflection of
the fast-moving nature of the field.
In general, the reviews are erudite and written in an interesting
variety of styles. All attempt to address the relevance of cell death
to their work and are relatively up-to-date, current to 1997.
However, most are hampered by lack of illustrations. For example,
long descriptions of life cycles of experimental plant and animal
subjects, or signal transduction pathways could have been simpli-
fied by the use of diagrams or models. A notable exception is the
review of genetic approaches to programmed cell death in the
nematode Caenorhabditis elegans, which is well written and not
broken up, unlike certain others, by long lists of cross-references.
This book is probably most suitable for those who have a good
understanding of cell death, rather than for those who had previ-
ously avoided the field. Its strength lies in the global view it
provides in one source. It is more a selection of accounts rather
than a comprehensive evaluation — possibly an unrealistic ideal,
considering the range of disciplines covered.
Finally, the book did reach its stated aim of making me evaluate
my work, by introducing to me the term ￿retrorecognition￿ in its
first chapter. This is the phenomenon by which scientific or other
anomalies are not recognized until they have been given an expla-
nation in a new conceptual framework (Lightman and Gingerich,
1991). Having produced several anomalies in my own scientific
research, I have realized it is just frameworks that I am seeking.
Dr Kathreena M Kurian
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Clinical Trials in Oncology
Edited by Green, Bendetti and Crawley: Publication details,
£45, ISBN 412–996316. Chapman and Hall: London
Clinical Trials in Oncology is based entirely on the experience
of the Southwest Oncology Group statistical centre, Seattle,
Washington, USA. All the examples are taken from trials
conducted by the Southwest Oncology Group (SWOG) over the
past 40 years.
Over this period, it is clear that the development of methodolo-
gies, policies and protocols have led to the present robust and well-
defined guidelines on how clinical trials in oncology should be
organized.
This book should be read by anyone who is thinking of setting
up a trials group, be it for single-centre or for multicentre studies.
More specifically, it should be read by anyone who is thinking of
entering patients into trials organized by a trials group. Equally,
medical staff already involved in entering patients into trials will
benefit from reading the sections of the book relevant to them.
The book is not mathematical, it is almost entirely descriptive,
and its examples illustrate good and bad aspects of past trial
designs. There are many references to the more technical aspects
for those who need to know more.
After a brief introductory chapter, there is a chapter on statistical
concepts. This can best be summarized by the last paragraph: ￿This
chapter has introduced key statistical concepts and analyses.
Understanding the basics will help in understanding why statisti-
cians choose specific designs and analyses in specific settings.
These choices are the subject of the rest of the book.￿
The third chapter covers the design of clinical trials. It briefly
discusses phase I trials and goes into more detail on phase II trials,
including the standard SWOG phase II trial design. It finishes with
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randomization. Throughout, it states the need for well-defined end
points.
Chapter 4 discusses multiarm trials, that is when there are more
than two treatment arms. The take-home message here is to ask
simple questions (compare just two arms) and get straightforward
answers, as opposed to asking many questions and running the risk
of unclear answers, especially if the sample size is not adequate for
the multiarm setting.
The next few chapters cover the problems and requirements of
clinical trial management. In chapter 6, they discuss data manage-
ment and quality control. They put forward the standard SWOG
protocol design. This should be read by all parties who are
thinking of setting up a multicentre clinical trial. Hopefully, they
will then appreciate the work involved and the disciplines
involved in organizing a successful trial. For those wishing to take
part in entering cases into trials, this should give them an insight
into what they are letting themselves in for!
The other two chapters in this section cover problems, pitfalls
and dilemmas of interim analysis, data monitoring committees and
reporting of results. These three chapters taken together cover the
many aspects of organizing clinical trials, whether they are single
or multicentre.
Chapter 8 covers the pitfalls of trying to overinterpret the results
from trials or studies. There is a section on using historical
controls and the inherent problems involved. Among other topics
discussed are dose intensity analysis and subset analyses. They
highlight what can go wrong.
The penultimate chapter is on exploratory analysis and the iden-
tification of prognostic factors using the Cox regression method.
They finish this chapter with a discussion on meta-analysis.
The last chapter is headed summary and conclusions. It briefly
summarizes their key points on protocol lead randomized clinical
trials. It also contains the mission statement of the SWOG statis-
tical centre.
The reader may feel that groups organizing multicentre clinical
trials are being overly prescriptive in their demands on the medical
collaborators who are actually entering patients. An addendum to
their mission statement on how others may see the work of a trials
centre interfering with getting results is included, statisticians like
to be unbiased! Hopefully, this book instructs the reader on why
randomized trials are needed and why they need to be well orga-
nized. A final remark is that all proceeds from this book will go to
cancer research.
Rick Swindell
IL-12: Chemical Immunology series Vol. 68
Edited by L Adorini: Publication details, pp. 204, £123.90,
ISBN 3–8055–6526–7. Karger: Basle, 1997
It seems quite amazing that only a few years ago a single textbook
could cover most of the information known about all characterized
cytokines, whereas now we have textbooks such as this devoted to
a single cytokine. There can be little doubt, however, that IL-12,
with its central role in the Th1/Th2 paradigm, does justify such a
volume.
The book, in common with most other multiauthor books, does
show considerable variation in style with regard to content and
emphasis of the individual chapters. There are ten chapters in total.
The first four chapters are fairly coherent, concentrating on struc-
tural and functional aspects of the cytokine and receptor complex
in the human and mouse, and by the end of these chapters the
reader has the impression of a good comprehensive review of the
subject.
The next chapter is concerned with the modulation of IL-12
activities by other cytokines, such as TGF-b, IFN-g and IL-4. This
chapter is based on experimental results from the authors￿ labora-
tory with an extended discussion of these results in the context of
other published data. There is no acknowledgement in the chapter
that the data presented have been published elsewhere, and one
must question the suitability of a largely review book such as this
including data that have not been published in a peer-reviewed
journal. This chapter concludes that the development of a Th1- or
Th2-dominated immune response depends on the presence and
concentration of IL-12 and IFN-g or IL-4 and TGF-b, respectively,
early in the immune response.
There are then three chapters devoted to the role of IL-12 in
infectious diseases. These are largely concerned with a few
organisms, such as Leishmania, Candida albicans, Toxoplasma
gondii and Trypanasoma cruzi. The first of this group of chapters
is also more of a paper than a review, with inclusion of experi-
mental data. The authors￿ data indicate that, contrary to other
published data, IL-4-deficient BALB/c mice can contain
Leishmania infection unlike the disease susceptible wild-type
BALB/c. They conclude that, while IL-4 is not the only factor
determining susceptibility, it does tip the balance towards a worse
outcome. Again, there is no indication that these data have been
reported in any peer-reviewed literature. This chapter is followed
by a philosophical discussion of the role of IL-12 in bridging
innate and adaptive responses with particular reference to Candida
albicans and makes interesting reading. The final chapter in this
group considers protozoal infections; there is inclusion of some
experimental data, but this chapter predominantly reviews the
field. It concludes that glycolipids from intracellular protozoa are
of importance in inducing IL-12 and other proinflammatory
cytokines from macrophages, providing an explanation for the
predominant Th1 response to these organisms.
The penultimate chapter would be of most interest to cancer
specialists and reviews the animal and human clinical trials
exploring the anti-tumour potential of IL-12. This is a comprehen-
sive review, but one has a feeling of d￿j￿ vu while reading this
chapter. With promising results in animal and in vitro models,
phase II human trials were started and then prematurely aban-
doned because of intolerable adverse side-effects such as gastro-
intestinal bleeding, asthenia and hepatotoxicity. New approaches
using gene therapy are under way, but at the time of preparation of
the book it was too early to assess the efficacy of these. This is a
very similar story to that for many of the other cytokines investi-
gated in earlier trials, e.g. TNF-a.
The final chapter is again a comprehensive review of IL-12
and Th1/Th2 responses in autoimmune diseases with discussion
of the potential for manipulation of Th1/Th2 responses as a
therapeutic approach to control of disease induction and
progression.
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gists working in the Th1/Th2 field. It represents a comprehensive
review of IL-12 up to the publication date and is very well refer-
enced throughout. However, while the tumour section is well
written and relevant it constitutes a relatively small section of the
book.
Professor P Riches and Dr TA Poulton,
Department of Immunology,
St George’s Hospital Medical School,
London SW17 0RE
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